BACKGROUND: Patients affected by angioedema due to hereditary and acquired C1-inhibitor (C1-INH) deficiency (HAE and AAE, respectively) report trouble accessing dental care, due to the risk of a life-threatening oropharyngeal and laryngeal attack triggered by dental procedures. The aim of this study was to assess the identification of hurdles in receiving dental care, and the effectiveness of short-term prophylaxis (STP) in preventing angioedema attacks. In addition, the study evaluated the impact of dental care in angioedema disease. All patients affected by angioedema due to C1-INH deficiency who were treated in the dentistry outpatient department of ASST Fatebenefratelli Sacco hospital (Milan, Italy) between 2009 and 2017 were considered for the analysis. Data were collected from patients' records.
RESULTS: Twenty-nine patients were analyzed (27 with HAE and 2 with AAE). Of these, 63.0% reported that they had previously experienced hurdles in accessing dental care. Among patients with pathological oral status, at the first visit, 59.26% patients had moderate-to-severe oral disease. Seventy-five dental procedures were performed in 20 patients. Sixty procedures were preceded by STP (58 with plasma-derived C1-INH and 2 with danazol) in patients with/without long-term prophylaxis (LTP). Post-procedural attacks occurred in two patients. One HAE patient undergoing a tooth extraction without STP/LTP experienced a laryngeal attack. The other post-procedural attack occurred in an AAE patient with anti-C1-INH antibodies with STP with pdC1-INH. The angioedema disease did not worsen in any patient after dental care, but improved in four of them.
CONCLUSIONS: Most C1-INH-HAE patients reported hurdles in receiving dental care. STP protects against attacks after dental procedures. Treating oral diseases results in improvement in the frequency of attacks.
STP with pdC1-INH was effective in preventing post-procedural attacks.
definitive efficacy language rests on non-comparable prophylaxis groups and only two wholly unprotected procedures
Most C1-INH-HAE patients reported hurdles in receiving dental care.
directly reported by 17 of 27 patients with available access data in one specialist-centre cohort
Treating oral diseases results in improvement in the frequency of attacks.
causal framing rests on an uncontrolled pre/post comparison with improvement observed in four patients
Derived from the full evaluation — not a separate score.
Strengths
The records show that 17 of 27 patients with available data reported hurdles in obtaining dental care, identifying a specific problem for dentists, referral centres, and affected patients.
↳ Results, paragraph 2; Conclusions, paragraph 1
The Methods specify STP drugs, doses, timing, long-term prophylaxis, and a 48-hour post-procedure attack window. Results distinguish the unprotected HAE extraction attack from the AAE breakthrough attack after pdC1-INH.
↳ Methods, Study Population and Endpoints; Results, prophylaxis and attack paragraphs
The Discussion compares the cohort with Bork's extraction data, the Berinert Registry, Italian guidance, infection-trigger research, and prior retrospective analyses. This places the observations within the existing clinical evidence trajectory.
↳ Discussion, STP, Bork, Magerl, Farkas, and guideline paragraphs
Limitations
Only two procedures received neither STP nor LTP, and prophylaxis status was intertwined with procedure and clinical context. The resulting groups cannot establish that STP caused the observed difference in attacks.
↳ Results, prophylaxis distribution; Discussion, STP effectiveness paragraphs
The reported improvement occurred in four of 19 patients after dental care, without statistical testing or control for concurrent prophylaxis, natural fluctuation, selection, or regression to the mean. This concern materially affects the paper's causal interpretation.
↳ Results, final paragraph; Discussion, oral-pathology impact paragraph; Conclusions, paragraph 3
The limitations say retrospective data require interventional confirmation, yet the Abstract and Conclusions state that STP protects and oral treatment produces improvement. This leaves the central claims more definitive than the acknowledged evidence permits.
↳ Discussion, limitations paragraph 3; Abstract Conclusions; Full-text Conclusions, paragraphs 2–3
The paper provides transparent procedural descriptions and a concrete account of dental-care barriers in a rare clinical population. Its lowest score is driven by the absence of comparable prophylaxis groups and by the uncontrolled one-year pre/post analysis used to infer benefit from dental treatment. The Discussion engages relevant retrospective studies and acknowledges that interventional confirmation is needed, but the Abstract and Conclusions retain definitive efficacy language. The study is therefore most useful as corroborative and hypothesis-generating evidence rather than as an independent basis for causal treatment guidance.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
Limited2.5
Confidence mediumThe study adds rare-disease observations on dental-care barriers and a hypothesis-generating association between dental treatment and subsequent attack frequency. Its prophylaxis result is mainly incremental because larger retrospective studies and guidelines already support STP.
“17/27 patients (63.0%) encountered hurdles in accessing dental care”
The paper defines prophylaxis regimens, procedures, a 48-hour outcome window, and one-year pre/post periods, but it provides no comparable untreated analysis or confounding strategy. Clinical selection, concurrent prophylaxis, attrition, and an unvalidated oral-severity score materially limit causal interpretation.
“Only two procedures in two hereditary angioedema patients were not preceded by any type of prophylaxis”
The aims, methods, results, and discussion are readily followable, with numerical findings tied to the stated endpoints. Definitive phrases such as “was effective” and “results in improvement” communicate greater certainty than the observational analyses support.
“STP with pdC1-INH was effective in preventing post-procedural attacks.”
The Discussion engages relevant retrospective STP studies, guidelines, trigger-factor research, and the AAE antibody exception. Although the limitations acknowledge retrospective records and request confirmatory studies, the Conclusions retain definitive causal interpretations.
“Further interventional studies... are needed in order to confirm these conclusions.”
Concerns4 of 4 checks
The reported observations are broadly coherent, but the paper interprets them as causal evidence despite an uncontrolled design with only two procedures receiving no prophylaxis and no adjustment for clinical selection or concurrent prophylaxis. The dental-care improvement claim likewise relies on an uncontrolled pre/post comparison.
Ethics approval, Helsinki compliance, and written informed consent are declared. No research-conduct concern is established from the supplied text; the referenced S1 Data file remains an assessability gap only.
Flags: 2 declared / 5 total
14 of 14 checkable references verified
14 references in manuscript
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
Where this paper’s evidence sits on the path from initial observation to real-world use.
The data come from real-world specialist practice and can inform referral-centre planning and rescue preparedness. The uncontrolled prophylaxis allocation and sparse untreated observations prevent a deployment-ready estimate of effectiveness.
“rescue therapy should always be available”
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine
Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.
Well-supportedRiedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine
Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate
SupportedCohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine
NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.
Tentative